AMED Quick Quote AMED - Free Report) came out with quarterly earnings of $1.47 per share, beating the Zacks Consensus Estimate of $1.23 per share. This compares to earnings of $1.69 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 19.51%. A quarter ago, it was expected that this home health care and hospice services provider would post earnings of $1.11 per share when it actually produced earnings of $1.23, delivering a surprise of 10.81%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
, which belongs to the Zacks Medical - Outpatient and Home Healthcare industry, posted revenues of $557.89 million for the quarter ended June 2022, missing the Zacks Consensus Estimate by 4.10%. This compares to year-ago revenues of $564.17 million. The company has topped consensus revenue estimates just once over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Amedisys shares have lost about 21.6% since the beginning of the year versus the S&P 500's decline of -17.7%.
What's Next for Amedisys?
While Amedisys has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this
earnings release, the estimate revisions trend for Amedisys: unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #5 (Strong Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $1.38 on $599.03 million in revenues for the coming quarter and $5.29 on $2.35 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Outpatient and Home Healthcare is currently in the bottom 44% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the same industry, Elanco Animal Health Incorporated (
ELAN Quick Quote ELAN - Free Report) , is yet to report results for the quarter ended June 2022. The results are expected to be released on August 8.
This company is expected to post quarterly earnings of $0.26 per share in its upcoming report, which represents a year-over-year change of -7.1%. The consensus EPS estimate for the quarter has been revised 0.3% higher over the last 30 days to the current level.
Elanco Animal Health Incorporated's revenues are expected to be $1.18 billion, down 7.6% from the year-ago quarter.